STOK vs. ARQT

Last updated Jun 4, 2026

STOK (Stoke Therapeutics, Inc.) and ARQT (Arcutis Biotherapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, STOK returned -4.61%/yr vs -4.14%/yr for ARQT. At a 0.33 correlation, their price movements are largely independent.

Performance

STOK vs. ARQT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Stoke Therapeutics, Inc. (STOK) and Arcutis Biotherapeutics, Inc. (ARQT). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, STOK achieves a -7.18% return, which is significantly higher than ARQT's -26.48% return.

STOK

• 1D: 2.72%
• 1M: -13.81%
• YTD: -7.18%
• 6M: -4.84%
• 1Y: 170.28%
• 3Y*: 34.27%
• 5Y*: -4.61%
• 10Y*: —

ARQT

• 1D: 2.69%
• 1M: -9.11%
• YTD: -26.48%
• 6M: -28.74%
• 1Y: 60.89%
• 3Y*: 37.57%
• 5Y*: -4.14%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

STOK vs. ARQT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
STOK Stoke Therapeutics, Inc.	-7.18%	187.76%	109.70%	-43.01%	-61.53%	-61.26%	121.49%
ARQT Arcutis Biotherapeutics, Inc.	-26.48%	108.47%	331.27%	-78.18%	-28.64%	-26.27%	29.04%

Correlation

The correlation between STOK and ARQT is 0.35, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.35
Correlation (3Y) Calculated over the trailing 3-year period	0.33
Correlation (5Y) Calculated over the trailing 5-year period	0.35
Correlation (All Time) Calculated using the full available price history since Feb 3, 2020	0.33

Fundamentals

Market Cap STOK : $1.86B ARQT : $2.76B
EPS STOK : -$2.85 ARQT : -$0.02
PS Ratio STOK : 54.74 ARQT : 6.74
PB Ratio STOK : 4.70 ARQT : 14.56
Total Revenue (TTM) STOK : $32.08M ARQT : $415.62M
Gross Profit (TTM) STOK : $23.81M ARQT : $377.98M
EBITDA (TTM) STOK : -$179.29M ARQT : $12.21M

Return for Risk

STOK vs. ARQT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

STOK

STOK Risk / Return Rank: 91
STOK Sharpe Ratio Rank: 93
STOK Sortino Ratio Rank: 90
STOK Omega Ratio Rank: 89
STOK Calmar Ratio Rank: 90
STOK Martin Ratio Rank: 92

ARQT

ARQT Risk / Return Rank: 71
ARQT Sharpe Ratio Rank: 73
ARQT Sortino Ratio Rank: 72
ARQT Omega Ratio Rank: 70
ARQT Calmar Ratio Rank: 70
ARQT Martin Ratio Rank: 71

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

STOK vs. ARQT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Stoke Therapeutics, Inc. (STOK) and Arcutis Biotherapeutics, Inc. (ARQT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	STOK	ARQT	Difference
Sharpe ratio: Return per unit of total volatility	2.66	1.06	+1.60
Sortino ratio: Return per unit of downside risk	3.28	1.86	+1.42
Omega ratio: Gain probability vs. loss probability	1.41	1.23	+0.18
Calmar ratio: Return relative to maximum drawdown	4.61	1.63	+2.98
Martin ratio: Return relative to average drawdown	14.14	3.90	+10.24
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

STOK vs. ARQT - Sharpe Ratio Comparison

The current STOK Sharpe Ratio is 2.66, which is higher than the ARQT Sharpe Ratio of 1.06. The chart below compares the historical Sharpe Ratios of STOK and ARQT, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	STOK	ARQT	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.66	1.06	+1.60
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.06	-0.06	0.00
Sharpe Ratio (All Time) Calculated using the full available price history	0.03	-0.00	+0.03

Drawdowns

STOK vs. ARQT - Drawdown Comparison

The maximum STOK drawdown since its inception was -95.17%, roughly equal to the maximum ARQT drawdown of -95.02%. Use the drawdown chart below to compare losses from any high point for STOK and ARQT.

Drawdown Indicators

	STOK	ARQT	Difference
Max Drawdown Largest peak-to-trough decline	-95.17%	-95.02%	-0.15%
Max Drawdown (1Y) Largest decline over 1 year	-37.16%	-37.50%	+0.34%
Max Drawdown (3Y) Largest decline over 3 years	-75.62%	-83.24%	+7.62%
Max Drawdown (5Y) Largest decline over 5 years	-91.80%	-93.67%	+1.87%
Current Drawdown Current decline from peak	-57.80%	-42.27%	-15.53%
Average Drawdown Average peak-to-trough decline	-62.31%	-50.15%	-12.16%
Ulcer Index Depth and duration of drawdowns from previous peaks	12.09%	15.65%	-3.56%

Volatility

STOK vs. ARQT - Volatility Comparison

The current volatility for Stoke Therapeutics, Inc. (STOK) is 12.34%, while Arcutis Biotherapeutics, Inc. (ARQT) has a volatility of 20.15%. This indicates that STOK experiences smaller price fluctuations and is considered to be less risky than ARQT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	STOK	ARQT	Difference
Volatility (1M) Calculated over the trailing 1-month period	12.34%	20.15%	-7.81%
Volatility (6M) Calculated over the trailing 6-month period	41.46%	36.79%	+4.67%
Volatility (1Y) Calculated over the trailing 1-year period	65.08%	57.58%	+7.50%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	80.88%	71.79%	+9.09%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	80.43%	76.98%	+3.45%

Dividends

STOK vs. ARQT - Dividend Comparison

Neither STOK nor ARQT has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both STOK and ARQT in my portfolio?

STOK and ARQT have a correlation of 0.35, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, STOK or ARQT?

ARQT has higher volatility (20.15%) compared to STOK (12.34%). In terms of maximum drawdown, STOK dropped -95.17% vs ARQT's -95.02%.

Which has better risk-adjusted returns?

STOK currently has the higher Sharpe Ratio (2.66 vs 1.06), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.